RiskofNeverTakingHRT/Data

RiskofNeverTakingHRT/Data:SymptomSeverity Mitigation

MitigationStrategy	Symptom_Improvement_Percent	Associated_Risks_Text
No Treatment	0	No associated risks.
Local HRT	80	Local HRT has a very low risk profile with minimal systemic absorption.
Systemic HRT	90	For every 1,000 women who use systemic HRT for 5 years, there are approximately 4 additional cases of breast cancer. The risk of a blood clot is about 8 additional cases per 10,000 women per year with oral HRT.
Non-Hormonal Lubricants/Moisturizers	50	Non-hormonal treatments have a very low risk profile.

The table above shows the approximate percentage of women who report significant improvement in genitourinary symptoms of menopause (GSM) based on different mitigation strategies. The associated risks for systemic HRT are based on a 5-year period.

• The Women's Health Initiative Randomized Controlled Trial and Progestin Therapy
• Hormone Therapy and Menopause: An Overview
• The North American Menopause Society - Menopause and Vaginal Dryness

RiskModel: RiskofNeverTakingHRT/Data:GSM_Risk_Model
Content: 
'''Selected Mitigation Strategy:''' {MitigationStrategy}
<br>
The likelihood of significant symptom improvement has a {Symptom_Improvement_Percent}% chance of success.
<br><br>
'''Associated Risks:'''
<br>
{Associated_Risks_Text}

The baseline risk of developing symptoms is between 40% and 84%.

Data and risk models are used on the main page.

Initially created by Gemini (Google).